GLOBAL EQUITY ALLOCATION FUND

Investment Review: Quarter Ending December 31, 2022

OVERVIEW

The GMO Global Equity Allocation Fund seeks total return greater than that of its benchmark, the MSCI ACWI.

PERFORMANCE (%)

Net of Fees, Class III, Fair Value, USD	+13.56
Gross of Fees, Class III, Local Close, USD	+13.38
MSCI ACWI +[1]	+9.76
Value Added	**+3.62**

Major Performance Drivers

- Top-down asset allocation was positive for the quarter, driven by our bias away from the U.S. within Developed equities.
- Security selection was also positive for the quarter, helped by it being a good quarter for Value, especially in Developed Markets.

Emerging Market equities, with an emphasis on undervalued stocks within attractively valued countries/sectors, represented 22.9% of the total portfolio weight on average during the quarter. Our overweight position in emerging equities had limited impact on relative performance as the MSCI Emerging Market index returned 9.7%, broadly in line with the MSCI ACWI return of 9.8%, despite a significant rebound in China. Security selection was positive, as the Emerging Market portfolio returned 9.6%, a little behind the MSCI Emerging Market Value index return of 9.8%, but the Emerging Markets ex-China portfolio returned 12.5%, well ahead of both the MSCI Emerging ex-China index return of 8.0% and the MSCI Emerging ex-China Value index return of 8.4%. An overweight position in Petroleo Brasileiro (Brazil Energy) featured in the top five biggest individual detractors from relative performance at the total portfolio level.

U.S. equities accounted for 33.3% of the total portfolio on average through the quarter, made up of 4.4% in U.S. Small Cap Value equity, 5.3% in U.S. Small Cap Quality equity, 8.8% in broad U.S. equity, 2.3% in a newly established allocation to U.S. Opportunistic Value equity, and the remainder in the Quality and Quality Cyclicals strategies. This leaves the portfolio 28.2% underweight U.S. equities in total, and this added to relative performance for the quarter as the MSCI USA index returned 7.0%, well behind the MSCI ACWI index. Security selection in the U.S. was also positive as all the underlying strategies outperformed – in aggregate, our U.S. portfolio returned 10.9%. Underweight positions in Tesla (Consumer Discretionary), Amazon (Consumer Discretionary), Apple (Information Technology), and Alphabet (Communication Services) featured in the five biggest individual contributors to relative performance for the quarter. On the flipside, an underweight position in JPMorgan Chase (U.S. Financials) featured in the top five biggest individual detractors from performance.

Developed ex-U.S. equities accounted for an average weight of 42.2% of the portfolio for the quarter, including the dedicated Japan Value position and some exposure from the Quality and Quality Cyclicals strategies. This overweight position in developed ex-U.S. had a strong positive impact on relative performance as the MSCI EAFE index returned 17.3%, well ahead of MSCI ACWI – largely because of a softening U.S. dollar enhancing returns. Security selection within Developed was also positive for the quarter. An overweight position in Banco Bilbao (Spain Financials) featured in the top five biggest individual contributors to relative performance at the total portfolio level. On the flipside, an overweight position in Roche

Performance data quoted represents past performance and is not indicative of future results. The investment return and principal value of an investment will fluctuate so that an investors shares, when redeemed, may be worth more or less than their original cost. Current performance data may be lower or higher than the performance data provided herein. To obtain performance information to the most recent month-end, visit www.gmo.com. Gross Expense Ratio of 0.60% is equal to the Funds Total Annual Operating Expenses set forth in the Funds most recent prospectus dated June 30, 2022.

ANNUALIZED RETURN (%) AS OF 12/31/2022



Inception date: 11/26/1996
Includes purchase premiums and redemption fees impact if applicable.

40 Rowes Wharf | Boston, Massachusetts 02110
(617) 330-7500 | www.gmo.com | GMO LLC © 2022

(Switzerland Health Care) and Canon Inc. (Japan Information Technology), along with an underweight position in Novo Nordisk (Denmark Health Care) featured in the five biggest detractors from relative performance for the quarter.

Portfolio weights, as a percent of equity, for the positions mentioned were: Petroleo Brasileiro (0.7%), Tesla (0.0%), Amazon (0.4%), Apple (1.0%), Alphabet (0.7%), JPMorgan Chase (0.1%), Banco Bilbao (0.9%), Roche (1.6%), Canon Inc. (0.7%), and Novo Nordisk (0.0%).

An investor should consider the fund's investment objectives, risks, charges and expenses before investing. This and other important information can be found in the fund's prospectus. To obtain a prospectus please visit www.gmo.com. Read the prospectus carefully before investing.

Risks associated with investing in the Fund may include, Market Risk-Equities, Management and Operational Risk, Non-U.S. Investment Risk, Derivatives and Short Sales Risk and Fund of Funds Risk. For a more complete discussion of these risks and others, please consult the Fund's prospectus. The GMO Trust funds are distributed in the United States by Funds Distributor LLC. GMO and Funds Distributor LLC are not affiliated.

[1] The MSCI ACWI (All Country World) + Index is an internally maintained benchmark computed by GMO, comprised of (i) the GMO Global Equity Index, an internally maintained benchmark computed by GMO, comprised of 75% S&P 500 Index and 25% MSCI ACWI ex-U.S. Index (MSCI Standard Index Series, net of withholding tax) through 5/31/2008 and (ii) the MSCI ACWI Index (MSCI Standard Index Series, net of withholding tax) thereafter. S&P does not guarantee the accuracy, adequacy, completeness or availability of any data or information and is not responsible for any errors or omissions from the use of such data or information. Reproduction of the data or information in any form is prohibited except with the prior written permission of S&P or its third party licensors. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder.